Holen Sie sich die Stockscreener-App
14.60
3.69%
-0.56
Handel nachbörslich:
14.25
-0.35
-2.40%
Schlusskurs vom Vortag:
$15.16
Offen:
$15.24
24-Stunden-Volumen:
1.15M
Relative Volume:
1.39
Marktkapitalisierung:
$1.55B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-4.7249
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
+9.36%
1M Leistung:
+24.57%
6M Leistung:
+94.67%
1J Leistung:
-14.62%
1-Tages-Spanne:
$14.26
$15.24
1-Wochen-Bereich:
$13.61
$16.12
52-Wochen-Spanne:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
14.60 | 1.61B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Will Arcus Biosciences Inc. stock benefit from sector rotationJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
Price momentum metrics for Arcus Biosciences Inc. explainedWeekly Trend Summary & AI Driven Price Predictions - newser.com
Arcus Biosciences (NYSE:RCUS) COO Jennifer Jarrett Sells 37,792 Shares of Stock - MarketBeat
60,300 Options at $15.05 — Arcus Biosciences Grants 30,150 RSUs under 2020 Inducement Plan - Stock Titan
Arcus Biosciences Hits Day High with Strong 8.46% Intraday Surge - Markets Mojo
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data By Investing.com - Investing.com Australia
Arcus Biosciences COO Jarrett sells $750k in shares By Investing.com - Investing.com Canada
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data - Investing.com India
Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? - MSN
Weiss Ratings Reaffirms "Sell (D-)" Rating for Arcus Biosciences (NYSE:RCUS) - MarketBeat
RCUS: Truist Securities Raises Price Target for Arcus Biosciences | RCUS Stock News - GuruFocus
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment - inkl
A Fresh Look at Arcus Biosciences (RCUS) Valuation After New Casdatifan Data and Expanded Pipeline Initiatives - Yahoo Finance
Arcus Biosciences announces new anti-inflammation programs - BioWorld MedTech
Truist Raises Price Target on Arcus Biosciences to $39 From $32, Keeps Buy Rating - MarketScreener
Arcus Biosciences Presents Promising ARC-20 Study Data - MSN
Why Is Arcus Biosciences Stock Trading Higher On Monday? - Sahm
Arcus Biosciences (NYSE:RCUS) Trading Up 15.2%Here's What Happened - MarketBeat
Transcript : Arcus Biosciences, Inc.Shareholder/Analyst Call - MarketScreener
Arcus Biosciences (RCUS) Sees Promising Results in Latest Study - GuruFocus
Arcus Biosciences (RCUS) Shares Positive Data on Casdatifan for Metastatic RCC - GuruFocus
Arcus Biosciences presents new data for its HIF-2a inhibitor casdatifan - MarketScreener
Arcus Biosciences reports positive casdatifan data, expands into inflammation - StreetInsider
Can momentum traders help lift Arcus Biosciences Inc.Weekly Stock Recap & Weekly High Return Forecasts - newser.com
What drives Arcus Biosciences Inc stock priceSector Performance Drivers & Free Superior Stock Performance - earlytimes.in
How to use Fibonacci retracement on Arcus Biosciences Inc.Trade Analysis Summary & Safe Capital Allocation Plans - newser.com
Published on: 2025-10-05 02:17:26 - newser.com
Pleasing Signs As A Number Of Insiders Buy Arcus Biosciences Stock - simplywall.st
Technical analysis overview for Arcus Biosciences Inc. stockJuly 2025 Catalysts & Weekly Momentum Picks - newser.com
Arcus Biosciences, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
Arcus Biosciences Hits Day High with 9.94% Surge in Strong Intraday Performance - Markets Mojo
Barclays Keeps Their Buy Rating on Arcus Biosciences (RCUS) - The Globe and Mail
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,831 Shares - MarketBeat
Published on: 2025-09-30 20:31:22 - newser.com
Insider Sell: Alexander Azoy Sells Shares of Arcus Biosciences I - GuruFocus
What analysts say about Arcus Biosciences Inc stockIndustrial Stocks Review & Big Profit Small Investment - earlytimes.in
Arcus Biosciences Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Arcus Biosciences Inc Stock Analysis and ForecastMarket Rumors and News & Affordable Investment Strategies - earlytimes.in
Published on: 2025-09-29 02:24:19 - newser.com
Voya Investment Management LLC Acquires 17,929 Shares of Arcus Biosciences, Inc. $RCUS - Defense World
Is Arcus Biosciences Inc a good long term investmentDividend Stability Analysis & Maximize Returns With Insights - earlytimes.in
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arcus Biosciences Inc-Aktie (RCUS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jarrett Jennifer | Chief Operating Officer |
Oct 06 '25 |
Option Exercise |
1.23 |
12,500 |
15,345 |
226,732 |
| Jarrett Jennifer | Chief Operating Officer |
Oct 08 '25 |
Sale |
15.05 |
37,792 |
568,611 |
214,232 |
| Jarrett Jennifer | Chief Operating Officer |
Oct 06 '25 |
Sale |
14.54 |
12,500 |
181,801 |
214,232 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):